Cargando…

A Case of Carbamazepine-Induced Aggravation of Self-Limited Epilepsy with Centrotemporal Spikes Epilepsy and Valproate-Induced Hyperammonemic Encephalopathy in a Child with Heterozygous Gene Variant of Carbomoyl Phosphatase Synthetase Deficiency

Antiepileptics drugs are the mainstay of the management of epilepsy in children. Sodium valproate (VPA) and carbamazepine (CBZ) are widely used medications in childhood epilepsy. Hyperammonemia has been described as a known side effect of valproate therapy. It is known that VPA-associated HA is comm...

Descripción completa

Detalles Bibliográficos
Autores principales: Kankananarachchi, Imalke, Jasinge, Eresha, Hewawitharana, Gemunu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741391/
https://www.ncbi.nlm.nih.gov/pubmed/35003817
http://dx.doi.org/10.1155/2021/2362679
_version_ 1784629479257145344
author Kankananarachchi, Imalke
Jasinge, Eresha
Hewawitharana, Gemunu
author_facet Kankananarachchi, Imalke
Jasinge, Eresha
Hewawitharana, Gemunu
author_sort Kankananarachchi, Imalke
collection PubMed
description Antiepileptics drugs are the mainstay of the management of epilepsy in children. Sodium valproate (VPA) and carbamazepine (CBZ) are widely used medications in childhood epilepsy. Hyperammonemia has been described as a known side effect of valproate therapy. It is known that VPA-associated HA is common among patients who hold genetic mutations of the carbomoyl phosphatase synthase 1 gene (CPS1). Aggravation of self-limited epilepsy with centrotemporal spikes (SLECTS) is a rare side effect of CBZ. Here, we present a child who had CBZ-induced aggravation of rolandic epilepsy and VPA-induced HA encephalopathy in the background of an unrecognised heterozygous gene variant of CPS1. An 8-year-old boy with SLECTS presented with a history of abnormal behaviours and drowsiness. He was apparently well until six years when he developed seizures in favour of rolandic epilepsy. His electroencephalogram (EEG) showed bilateral predominantly on the right-sided central-temporal spikes and waves. The diagnosis of SLECTS was made, and he was commenced on CBZ. Though he showed some improvement at the beginning, his seizure frequency increased when the dose of CBZ was increased. His repeat EEG showed electrical status in slow-wave sleep, and CBZ was stopped. Subsequently, he was started on VPA, and with that, he developed features of encephalopathy. He had elevated serum ammonia with normal liver functions. VPA was stopped with the suspicion of VPA-induced hyperammonemia. Tandem mass spectrometry did not show significant abnormality in the amino acid profile. Specific genetic analysis revealed a c.2756 C > T.p (Ser919Leu) heterozygote genetic mutation of the CSP 1 gene. This is a classic example where side effects of treatment determine the choice of antiepileptics drugs (AEDs) in childhood epilepsy. It is essential to keep in mind that SLECTS can be aggravated with certain AEDs, and VPA-induced HA in the absence of live failure could be due to underlying inherited metabolic disorders.
format Online
Article
Text
id pubmed-8741391
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-87413912022-01-08 A Case of Carbamazepine-Induced Aggravation of Self-Limited Epilepsy with Centrotemporal Spikes Epilepsy and Valproate-Induced Hyperammonemic Encephalopathy in a Child with Heterozygous Gene Variant of Carbomoyl Phosphatase Synthetase Deficiency Kankananarachchi, Imalke Jasinge, Eresha Hewawitharana, Gemunu Case Rep Neurol Med Case Report Antiepileptics drugs are the mainstay of the management of epilepsy in children. Sodium valproate (VPA) and carbamazepine (CBZ) are widely used medications in childhood epilepsy. Hyperammonemia has been described as a known side effect of valproate therapy. It is known that VPA-associated HA is common among patients who hold genetic mutations of the carbomoyl phosphatase synthase 1 gene (CPS1). Aggravation of self-limited epilepsy with centrotemporal spikes (SLECTS) is a rare side effect of CBZ. Here, we present a child who had CBZ-induced aggravation of rolandic epilepsy and VPA-induced HA encephalopathy in the background of an unrecognised heterozygous gene variant of CPS1. An 8-year-old boy with SLECTS presented with a history of abnormal behaviours and drowsiness. He was apparently well until six years when he developed seizures in favour of rolandic epilepsy. His electroencephalogram (EEG) showed bilateral predominantly on the right-sided central-temporal spikes and waves. The diagnosis of SLECTS was made, and he was commenced on CBZ. Though he showed some improvement at the beginning, his seizure frequency increased when the dose of CBZ was increased. His repeat EEG showed electrical status in slow-wave sleep, and CBZ was stopped. Subsequently, he was started on VPA, and with that, he developed features of encephalopathy. He had elevated serum ammonia with normal liver functions. VPA was stopped with the suspicion of VPA-induced hyperammonemia. Tandem mass spectrometry did not show significant abnormality in the amino acid profile. Specific genetic analysis revealed a c.2756 C > T.p (Ser919Leu) heterozygote genetic mutation of the CSP 1 gene. This is a classic example where side effects of treatment determine the choice of antiepileptics drugs (AEDs) in childhood epilepsy. It is essential to keep in mind that SLECTS can be aggravated with certain AEDs, and VPA-induced HA in the absence of live failure could be due to underlying inherited metabolic disorders. Hindawi 2021-12-31 /pmc/articles/PMC8741391/ /pubmed/35003817 http://dx.doi.org/10.1155/2021/2362679 Text en Copyright © 2021 Imalke Kankananarachchi et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kankananarachchi, Imalke
Jasinge, Eresha
Hewawitharana, Gemunu
A Case of Carbamazepine-Induced Aggravation of Self-Limited Epilepsy with Centrotemporal Spikes Epilepsy and Valproate-Induced Hyperammonemic Encephalopathy in a Child with Heterozygous Gene Variant of Carbomoyl Phosphatase Synthetase Deficiency
title A Case of Carbamazepine-Induced Aggravation of Self-Limited Epilepsy with Centrotemporal Spikes Epilepsy and Valproate-Induced Hyperammonemic Encephalopathy in a Child with Heterozygous Gene Variant of Carbomoyl Phosphatase Synthetase Deficiency
title_full A Case of Carbamazepine-Induced Aggravation of Self-Limited Epilepsy with Centrotemporal Spikes Epilepsy and Valproate-Induced Hyperammonemic Encephalopathy in a Child with Heterozygous Gene Variant of Carbomoyl Phosphatase Synthetase Deficiency
title_fullStr A Case of Carbamazepine-Induced Aggravation of Self-Limited Epilepsy with Centrotemporal Spikes Epilepsy and Valproate-Induced Hyperammonemic Encephalopathy in a Child with Heterozygous Gene Variant of Carbomoyl Phosphatase Synthetase Deficiency
title_full_unstemmed A Case of Carbamazepine-Induced Aggravation of Self-Limited Epilepsy with Centrotemporal Spikes Epilepsy and Valproate-Induced Hyperammonemic Encephalopathy in a Child with Heterozygous Gene Variant of Carbomoyl Phosphatase Synthetase Deficiency
title_short A Case of Carbamazepine-Induced Aggravation of Self-Limited Epilepsy with Centrotemporal Spikes Epilepsy and Valproate-Induced Hyperammonemic Encephalopathy in a Child with Heterozygous Gene Variant of Carbomoyl Phosphatase Synthetase Deficiency
title_sort case of carbamazepine-induced aggravation of self-limited epilepsy with centrotemporal spikes epilepsy and valproate-induced hyperammonemic encephalopathy in a child with heterozygous gene variant of carbomoyl phosphatase synthetase deficiency
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741391/
https://www.ncbi.nlm.nih.gov/pubmed/35003817
http://dx.doi.org/10.1155/2021/2362679
work_keys_str_mv AT kankananarachchiimalke acaseofcarbamazepineinducedaggravationofselflimitedepilepsywithcentrotemporalspikesepilepsyandvalproateinducedhyperammonemicencephalopathyinachildwithheterozygousgenevariantofcarbomoylphosphatasesynthetasedeficiency
AT jasingeeresha acaseofcarbamazepineinducedaggravationofselflimitedepilepsywithcentrotemporalspikesepilepsyandvalproateinducedhyperammonemicencephalopathyinachildwithheterozygousgenevariantofcarbomoylphosphatasesynthetasedeficiency
AT hewawitharanagemunu acaseofcarbamazepineinducedaggravationofselflimitedepilepsywithcentrotemporalspikesepilepsyandvalproateinducedhyperammonemicencephalopathyinachildwithheterozygousgenevariantofcarbomoylphosphatasesynthetasedeficiency
AT kankananarachchiimalke caseofcarbamazepineinducedaggravationofselflimitedepilepsywithcentrotemporalspikesepilepsyandvalproateinducedhyperammonemicencephalopathyinachildwithheterozygousgenevariantofcarbomoylphosphatasesynthetasedeficiency
AT jasingeeresha caseofcarbamazepineinducedaggravationofselflimitedepilepsywithcentrotemporalspikesepilepsyandvalproateinducedhyperammonemicencephalopathyinachildwithheterozygousgenevariantofcarbomoylphosphatasesynthetasedeficiency
AT hewawitharanagemunu caseofcarbamazepineinducedaggravationofselflimitedepilepsywithcentrotemporalspikesepilepsyandvalproateinducedhyperammonemicencephalopathyinachildwithheterozygousgenevariantofcarbomoylphosphatasesynthetasedeficiency